Morningstar Acciones

Novonesis AS NSIS B StarRatingValueLabel_3Mr. Lee Davidson, Head of Quantitative Research

Último Precio
387,00
Cambio del día
4,30|1,12%

a 19/04/2024
18:50:46 CEST | DKK  Minimum 15 Minutes Delay.

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
387,90 - 388,20378,10 - 389,00356.165725.395179,70Bil
Último Cierre52 Week RangeP/BeneficioDividendo %ISIN
382,70274,60 - 421,7035,571,09DK0060336014

Cotización Novonesis AS

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
More...
Cuenta de Resultados
Ingresos14.951,0017.553,0017.899,00
Operating Income3.885,004.428,004.464,00
Resultado Neto3.146,003.676,003.024,00
Beneficio Básico por Acción11,3213,2910,92
Num Medio Acciones diluidas en circulación280279278
Balance
Activo Corriente7.823,009.241,009.462,00
Activos no corrientes16.944,0018.742,0018.929,00
Total Activo 24.767,0027.983,0028.391,00
Pasivo corriente5.673,006.963,007.262,00
Total Pasivo---
Total Equity11.827,0013.837,0013.978,00
Flujo de Caja
Flujo de caja operativo4.062,004.006,004.152,00
Inversiones de Capital-1.240,00-2.890,00-2.056,00
Flujo de Caja Libre2.822,001.116,002.096,00

En millones, excepto "EPS básico". Currency is DKK.

Perfil de la compañía

Novonesis AS formerly Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company is the world leader in industrial enzymes and microbial solutions, with a near-50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, working across more than 30 research and development and application centers and 23 manufacturing sites.

Sector

Materiales básicos

Industria

Productos Químicos Especializados

Estilo de acciones

Grande-Mixto

Fin Ejercicio Fiscal

diciembre

Empleados

6.756
Datos destacados
More...
Precio/Beneficio 12 m35,05
Precio/Valor contable12,71
Price/Sales TTM5,94
Crec Ingresos (media 3 a)8,50
Crec BPA (media 3 a)-
Margen operativo24,94
Margen neto16,89
ROE 12 m21,74
Deuda/Fondos propios0,33
Dividendos
AntLatest
Declared Date01/10/2309/04/24
Ex-Div11/10/2301/05/24
Paid17/10/2303/05/24
Amnt4,202,00
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. Reservados todos los derechos.

Términos de uso        Política Privacidad        Cookie Settings        Aviso Legal